Multiple Sclerosis

Cognitive impairment affects 50-70% of Multiple Sclerosis (MS) patients and is noted as one of the most disabling aspects of the disease. As such, addressing cognitive impairment and decline is vital in the development of MS treatments.

Cogstate supports your team in these efforts by providing highly sensitive and reliable digital cognitive testing, as well as endpoint data quality support for conventional assessments, such as the BICAMS, MSFC, and PASAT. We have the expertise to help you answer key drug development questions.

CONNECT WITH OUR TEAM

Improve Strategic Study Design

The Cogstate team of cognitive scientists and statisticians have the expertise to advise your team on vital study considerations, help you answer key drug development questions, and reduce risk and uncertainty in your trial.

With access to thousands of cognitive data profiles—and from decades supporting drug development work—Cogstate can advise your team on endpoint selection, powering decisions, and interpretation of study results supportive of product efficacy, safety, and differentiating claims.

Implement Robust Endpoint Data Quality Programs

From helping you establish rater qualification criteria, to tailored certification pathways that credit the experience of expert raters, to central monitoring programs that target clinician reviews where they’re needed most, Cogstate supports all aspects of rater training and endpoint data quality programs. Studies also benefit from our global network of 180 highly trained expert clinicians who provide assessment support in 40+ languages.

Leverage Sensitive and Reliable Digital Tests

Cogstate digital assessments provide rapid and reliable measurement of distinct domains affected by MS and enable you to capture a complete and nuanced picture of a subject’s cognitive state.

Cogstate tests are culture- and education-neutral and designed for repeated administration with minimal practice or learning effects, making them ideal for use in global clinical trials. Normative data is available for both clinical samples and healthy controls. Study teams can choose the tests that best suit their research questions. Each test has been used in drug trials.

Sample Multiple Sclerosis Battery

The tests included are a sample battery based on domains commonly impacted by MS. Final battery recommendations vary based on study needs.

Cogstate Tests:	• Detection (Psychomotor Function) • Identification (Attention) • One Card Learning (Visual Learning) • One Back (Working Memory) • Two Back (Working Memory) • International Shopping List (Verbal Learning) • Groton Maze Learning (Executive Function)
Length:	Between 5-40 minutes (depending on the number of tests included in the battery)
Administration:	Standardized
Data Processing and Scoring:	Automated
Application:	Phase I-IV
Culture and Language Neutral:	Yes

Case Study of MS Solutions in Action

Evaluating Cognitive Deterioration in MS Patients via Cogstate Digital Assessments

Cogstate supported safety assessment in a 24-month observational study of natalizumab in multiple sclerosis patients. 63 patients were treated and assessed prior to monthly infusions using a Cogstate battery and the Symbol Digit Modalities Test (SDMT). Using data from the Cogstate assessments, no patient showed evidence of sustained cognitive deterioration over the 24-month period. Data were relevant to ensuring long-term safety and sustained efficacy of treatment. (Gaudet D., et al., DOI: https://doi.org/10.1016/j.atherosclerosis.2021.06.789)

Multiple Sclerosis Featured Resources

Webinar

Selection of Peer Reviewed Publications in Multiple Sclerosis

Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review

Journal: Multiple Sclerosis: Clinical and Laboratory Research

Year Published: 2019

Brief Computer-Based Information Processing Measures are Linked to White Matter Integrity in Pediatric-Onset Multiple Sclerosis

Journal: Journal of Neuroimaging

Year Published: 2019

Monitoring cognitive change in multiple sclerosis using a computerized cognitive battery

Journal: Multiple Sclerosis Journal - Experimental Translational and Clinical

Year Published: 2018

Cognitive evolution in natalizumab-treated multiple sclerosis patients

Journal: Multiple Sclerosis Journal - Experimental Translational and Clinical

Year Published: 2017

Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing

Journal: Multiple Sclerosis: Clinical and Laboratory Research

Year Published: 2017

All Publications

Multiple Sclerosis

Cognitive impairment affects 50-70% of Multiple Sclerosis (MS) patients and is noted as one of the most disabling aspects of the disease. As such, addressing cognitive impairment and decline is vital in the development of MS treatments.

Improve Strategic Study Design

Implement Robust Endpoint Data Quality Programs

Leverage Sensitive and Reliable Digital Tests

Sample Multiple Sclerosis Battery

Case Study of MS Solutions in Action

Multiple Sclerosis Featured Resources

Digital Technologies for Assessing Patient Functioning in Multiple Sclerosis Clinical Trials

Reliable and Valid Cognitive Test Results Obtained from MS Patients Performing Self-Administered Computerized Assessment

Multiple Sclerosis Clinical Trial Solutions from Cogstate

Selection of Peer Reviewed Publications in Multiple Sclerosis

Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review

Brief Computer-Based Information Processing Measures are Linked to White Matter Integrity in Pediatric-Onset Multiple Sclerosis

Monitoring cognitive change in multiple sclerosis using a computerized cognitive battery

Cognitive evolution in natalizumab-treated multiple sclerosis patients

Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing

How can we help you optimize the measurement of brain health?